Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Andries, Koen, Villellas, Cristina, Coeck, Nele, Thys, Kim, Gevers, Tom, Vranckx, Luc, Lounis, Nacer, de Jong, Bouke C., Koul, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092087/
https://www.ncbi.nlm.nih.gov/pubmed/25010492
http://dx.doi.org/10.1371/journal.pone.0102135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092087/
https://www.ncbi.nlm.nih.gov/pubmed/25010492
http://dx.doi.org/10.1371/journal.pone.0102135

Ejemplares similares